Drug Profile
Research programme: buprenorphine depot - Encore Therapeutics
Alternative Names: ETI-311Latest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Encore Therapeutics
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Opioid-related disorders; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Opioid-abuse in USA (SC, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (SC, Controlled release)
- 26 Sep 2011 Research programme: buprenorphine depot is available for licensing worldwide as of 26 Sep 2011